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Ghrelin, a gastric peptide hormone, has been reported to regulate growth hormone secretion
and energy homeostasis. Here we show that ghrelin promotes neural proliferation in vivo and
in vitro in the rat dorsal motor nucleus of the vagus (DMNV). Ghrelin receptor mRNA and
immunoreactivity were detected in tissues from DMNV. Systemic administration of ghrelin
(130 nmol kg−1) significantly increased 5-bromo-2′-deoxyuridine (BrdU) incorporation in the
DMNV in adult rats with cervical vagotomy (BrdU positive cells; from 27 ± 4 to 69 ± 14 n = 5,
P < 0.05). In vitro, exposure of cultured DMNV neurones to ghrelin significantly increased
the percentage of BrdU incorporation into cells in both dose-dependent (10−9–10−6 M),
and time-dependent (6 h to 48 h) manners. Ghrelin significantly increased voltage-activated
calcium currents in isolated single DMNV neurones from a mean maximal change of
141 ± 26 pA to 227 ± 37 pA. Upon removal of ghrelin, calcium currents slowly returned
to baseline. Blocking L-type calcium channels by diltiazem (10 µM) significantly attenuated
ghrelin-mediated increments in BrdU incorporation (n = 5, P < 0.05). Ghrelin acts directly
on DMNV neurones to stimulate neurogenesis.
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Ghrelin, a novel 28 amino acid peptide, is secreted by
gastric oxyntic glands and circulates in blood (Kojima
et al. 1999). It is an endogenous ligand for the growth
hormone secretagogue receptor and has been reported
to stimulate growth hormone release in human and
rat, following either peripheral or central administration
(Kojima et al. 1999; Wren et al. 2000; Takaya et al.
2000). Whereas ghrelin was originally reported to
stimulate growth hormone release, the wide distribution
of its receptor, growth hormone secretagogue receptor
(GHS-R), has suggested a potentially broader array of
actions. Expression of ghrelin and its related receptor in the
kidney indicates that ghrelin may play an important role in
the regulation of renal function (Mori et al. 2000). In rats,
ghrelin has been found to stimulate food intake (Wren
et al. 2000; Nakazato et al. 2001), to induce adiposity
(Tschop et al. 2000), and to increase body weight
(Wren et al. 2000; Tschop et al. 2000; Nakazato et al.
2001), suggesting a possible role in regulation of feeding
behaviour and energy metabolism. The up-regulation of
food intake by ghrelin is proposed to be mediated by a
central mechanism involving the regulation of the neuro-
peptide Y (NPY) and proopiomelanocortin (POMC)
neurones at the hypothalamic level (Nakazato et al. 2001;
Cowley et al. 2003).
In the gastrointestinal system, ghrelin has been recently
reported to regulate secretion of gastric acid (Masuda et al.
2000; Date et al. 2001), gastric motility (Masuda et al.
2000; Trudel et al. 2002), and pancreatic protein output
(Zhang et al. 2001). These results suggest that ghrelin
coordinates multiple functions in the gastrointestinal
system, although the mechanisms involved remain largely
unknown. The regulation of the gastrointestinal functions
by ghrelin has been demonstrated to be mediated by a
vagus nerve-dependent mechanism (Masuda et al. 2000;
Date et al. 2001). A recent report by Faulconbridge et al.
(2003) showed that direct application of ghrelin into the
dorsal vagal complex (DVC) stimulates food intake. These
studies suggest that ghrelin may act directly on the DVC
to regulate the feeding behaviour.
Neurogenesis, a process through which precursor cells
differentiate into a mature neuronal phenotype, persists in
the discrete regions of the adult brain. While the neuro-
genesis in the subventricular zone (SVZ) (Alvarez-Buylla
& Garcia-Verdugo, 2002) and the subgranular zone (SGZ)
(Seri et al. 2001) of the hippocampal dentate gyrus has been
described, it is unknown whether central parasympathetic
nuclei in the adult brain contain precursor cells. The dorsal
motor nucleus of the vagus (DMNV) contains neurones
that provide the parasympathetic efferent outflow to the
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gastrointestinal system. Despite the DMNV having been
demonstrated to undergo degeneration, regeneration and
changes in gene expression in response to mechanical
and chemical injury (Laiwand et al. 1987; Jacques et al.
1999; Chang et al. 2001; Yuan & Yang, 2002), the cellular
and molecular mechanisms underlying the process of
neural regeneration in the DMNV remain unknown.
While a variety of extracellular growth factors have been
reported to stimulate neurogenesis after brain injury
(Seri et al. 2001; Alvarez-Buylla & Garcia-Verdugo, 2002;
Jin et al. 2002a,b), the growth factors enhancing neural
regeneration in the DMNV remain to be characterized.
Previous studies (Gross et al. 1990; Hermann et al. 2001)
have demonstrated that the DMNV directly responds
to systemic endotoxin, suggesting that the DMNV may
possess the characteristics of a circumventricular organ,
which is essentially devoid of a blood–brain barrier. Since
ghrelin is circulating in the blood, it is possible that the
DMNV is exposed to, and directly responses to, ghrelin.
Because ghrelin acts as a potent growth factor to stimulate
cell proliferation (Pettersson et al. 2002; Zhang et al. 2004),
we hypothesize that ghrelin stimulates neural proliferation
in the DMNV.
The object of this study was to determine whether
ghrelin promotes neurogenesis in the DMNV. We report
here for the first time that in the DMNV (1) ghrelin
receptors are present; (2) systemic administration
of ghrelin stimulates BrdU incorporation in neuro-
nal precursors in adult rats; (3) in vitro, ghrelin
increases BrdU incorporation in both a dose- and
a time-dependent manner; (4) activation of ghrelin
receptors increases voltage-sensitive calcium currents;
and (5) blocking L-type calcium channels by diltiazem
attenuates ghrelin-mediated increments in BrdU
incorporation.
Methods
In vivo BrdU labelling and immunostainning
Male Sprague-Dawley rats (140–160 g, Harlan,
Indianapolis, IN, USA) were kept in individual cages
and were given chow food and water ad libitum. All
experiments were performed in rats anaesthetized with
intramuscular injection of a mixture of urethane and
ketamine (13 and 87 mg (kg body weight)−1, respectively)
and were approved by the University of Michigan
Committee on Use and Care of Animals. Ghrelin was
dissolved in 0.9% normal saline. Ghrelin (130 nmol kg−1)
or 0.9% saline was injected intravenously into male
rats twice daily 15 min before BrdU injection. BrdU
(50 mg kg−1 in saline i.p.) or saline was given twice daily
for 6 days. Unilateral cervical vagotomy was performed
prior to drug administration. Through a midline cervical
incision, right cervical vagal trunks were exposed
and sectioned. In some animals, sham-operation was
performed without sectioning vagus nerves.
After experiments, rats were anaesthetized by an intra-
muscular injection of sodium pentobarbital (75 mg
(kg body weight)−1) and perfused transcardially, first for
10 min with 100 ml of 0.1 m phosphate buffer (pH 7.4)
and then for 15 min with 150 ml of 4% paraformaldehyde
in 0.1 m phosphate buffer. The brainstem was removed
and postfixed for 2 days at 4◦C, then kept in 0.1 m
phosphate buffer containing 20% sucrose for 24 h. The
medulla oblongata containing the DMNV was sectioned
into 20 µm slices at the interaural level of −4.24 to
−5.08 mm according to the atlas of Paxinos and Watson
(1998), using a freezing microtome. All slices were
incubated for 24 h at 4◦C with a polyclonal rabbit
anti-BrdU antibody (3.5 µg ml−1) (Roche Diagnostics
Corporation, Indianapolis, IN, USA), then incubated
at room temperature for 2 h with biotin-conjugated
goat anti-rabbit IgG (1 : 400) (Vector Laboratories Inc.,
Burlingame, CA, USA), and finally incubated for 30 min
with Alexa Fluor 594 conjugated streptavidin (Vector
Laboratories Inc.). BrdU positive cells were counted in
three sections per animal at the level of area postrema
and means of cells per section were calculated. Data
were expressed as the mean ± s.e.m. Statistical differences
between control and treatment were assessed by ANOVA
with a post-test Tukey’s multiple comparison test. Data
were considered significant different when P < 0.05.
In vitro culture of DMNV
DMNV neurones were isolated from 3- to 5-day-old
Sprague-Dawley rats (Harlan, Indianapolis, IN, USA).
Rats were killed by an overdose of CO2, and the brain-
stem was rapidly removed and chilled at 0◦C in a dissection
solution containing (mm): NaCl 138, KCl 4, MgCl2 1, CaCl2
2, glucose 20, Hepes 10. Tissue blocks were prepared and
sectioned transversely into 350 µm slice at the level around
the obex using a Vibratome 3000 (Redding, CA, USA)
and two slices were taken. The DMNV area, which lies
immediately ventral to the nuclei of the solitary tract (NST)
and dorsal to the XII nucleus was excised using a dissecting
microscope. DMNV tissue was then digested in an enzyme
solution containing protease type XIV (0.6 mg ml−1) and
trypsin type I (0.4 mg ml−1) at 32◦C for 40 min. The
tissue was then dissociated by gentle trituration with
fire-polished Pasteur pipettes. Cells were plated onto
poly-d-lysine coated 35 mm culture dishes. Neurones were
maintained and cultured at 37◦C in an atmosphere of
5% CO2 in Neurobasal medium A (Gibco BRL, Grand
Island, NY, USA) containing 2% B27 supplement (Gibco
BRL), 2 mm glutamine, 1% penicillin and streptomycin,
and 5 ng ml−1 fibroblast growth factor β (FGF-β). After
4 days, one-half of the medium was replaced and
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experiments were conducted at 6–7 days unless indicated
otherwise.
RT-PCR
Total RNA was isolated from DMNV tissues prepared
freshly from 3- to 5-day-old rats using the RNeasy
Mini Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s directions. Single-strand cDNA synthesis
was performed as follows: 30 µl of reverse transcription
mixture contained 1 µg of DNase I pretreated total RNA,
0.75 µg of oligo d(T) primer, 6 µl of 5 × RT buffer,
10 mm dithiothreitol, 0.5 mm deoxynucleotides, 50 units
of RNase inhibitor and 240 units of reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). The RT reaction was
carried out at 40◦C for 70 min followed by heat inactivation
at 95◦C for 3 min. PCR primers used for ghrelin receptors
mRNA detection were deduced from rat published
sequences. β-Actin was used as an internal control. The
nucleotide sequences of sense and antisense primers with
the expected product size are follows: (1) ghrelin receptor:
TCG GAT CTG CTC ATC TTC CT (sense, bp 259–278)
and CAG CTC TCG CTG ACA AAC TG (antisense,
bp 355–374), 116 bp product; (2) β-actin: GTC GTA CCA
CTG GCA TTG TG (sense, bp 437–456) and CTC TCA
GCT GTG GTG GTG AA (antisense, bp 598–617), 181 bp
product. The cDNA was amplified by real time PCR, using
the Smart Cycler system (Cepheid). PCR was performed
in a total 25 µl volume, containing 2.5 µl cDNA, 5 mm
Figure 1. Expression of ghrelin receptor in DMNV
A, RT-PCR products of RNA extracted from 3- to 5-day-old rat DMNV tissues corresponding to ghrelin receptor
coding sequences (116 bp) are shown in lanes numbered 1 to 5 (each lane represents result from one individual
rat, the numbers correspond to each rat). Lanes M show molecular size markers. Other lanes represent the positive
control (+) from hypothalamus and the negative control (–) (RT-PCR performed without RNA reverse transcription).
The upper panel represents ghrelin receptor mRNA, whereas the lower panel shows β-actin mRNA (181 bp).
B, ghrelin receptor immunoreactivity was localized in DMNV neurones by a specific antibody against the 330–366
amino acid sequence of the human ghrelin receptor 1a (upper panel). Control tissue incubated with rabbit IgG
showed no significant staining (lower panel). Scale bar represents 100 µm.
MgCl2,0.2 mm dNTPs, 0.25 µm each primer, 1.25 U Ampli
Taq Polymerase (Roche), and 1 µl of a 800 × diluted SYBR
Green I stock (Roche). The PCR program was as follows:
hold 95◦C for 2 min; three-temperature cycle repeat for
45 times, 94◦C for 15 s, 70◦C for 15 s, 72◦C for 20 s.
Melt curve analysis was from 60◦C to 95◦C at 0.2◦C s−1
with Optics Ch1 On. PCR product was also visualized by
1.5% agarose gel electrophoresis. For negative controls,
PCR reactions were performed for the primer pairs
in the absence of transcript as others have reported.
Total RNA from rat hypothalamus was used as positive
control.
Whole cell patch-clamp recording
Experiments were performed at room temperature (22◦C).
Conventional whole cell patch-clamp recordings were
made under voltage clamp on DMNV neurones cultured
for 1–2 days using an Axopatch 200A amplifier (Axon
Instruments, Union City, CA, USA). Patch pipettes
(resistance 2–5 M) were filled with an intracellular
recording solution containing (mm): CsOH 112, CH3O4S
112, CsCl 13, MgCl2 1, EGTA 10, Hepes 30, ATP 2,
GTP 0.2, pH adjusted to 7.3. The extracellular solution
to isolate calcium current utilizing Ba2+ as a charge
carrier contained (mm): tetraethylammonium chloride
120, BaCl2 10, MgCl2 1, Hepes 10, and glucose 10,
pH adjusted to 7.3 with Tris. Data were filtered at
1 kHz, digitized via an Instrutech ITC-16 interface, leak
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subtracted, acquired and stored on a computer using
Pulse Control software (Drs Jack Herrington and Richard
Bookman, University of Miami Medical School, Miami,
FL, USA).
Immunofluorescent staining
Cultured DMNV neurones were fixed with 4%
paraformaldehyde for 10 min and processed for immuno-
fluorescent staining. Neurones were incubated at 4◦C
for 24 h with one of the following primary antibodies:
rabbit anti-microtubule-associated protein 2 (MAP-2)
Figure 2. BrdU incorporation into the dorsal vagal complex
Sections through the dorsal vagal complex were stained for BrdU and
visualized with Alexa fluor 594. BrdU labelling was increased in the
ipsilateral DVC 6 days after cervical vagotomy. In rats with cervical
vagotomy (n = 5), administration of ghrelin significantly increased
BrdU labelling in the DVC relative to controls receiving saline. Results
are representative of five experiments. The bar graphs show the
average BrdU labelling in the DMNV as means ± S.E.M. ∗P < 0.05
versus control. ∗∗P < 0.01 versus vagotomy + saline.
1 : 1000, Chemicon International, Temecula, CA, mouse
anti-Hu (1 : 100, Molecular Probes); rabbit anti-glial
fibrillary acidic protein (GFAP; 1 : 200, Santa Cruz
Biotechnology Inc., Santa Cruz, CA). Neurones were
then incubated at 22◦C for 1 h with secondary anti-
bodies: goat anti-rabbit FITC-conjugated IgG (1 : 100)
or goat anti-mouse FITC-conjugated IgG (1 : 50) (Santa
Cruz Biotechnology Inc.). Primary antibodies used for
double staining were: mouse anti-Hu (1 : 100, Molecular
Probes) and rat anti-BrdU (Serotec Inc., Raleigh, NC,
USA). Controls included omitting primary antibodies or
substituting primary antibodies with mouse or rat IgGs.
Cell proliferation assay
BrdU incorporation was performed according to
the manufacturer’s protocol (Roche Diagnostics
Corporation). In brief, BrdU (100 µm) was added to
cultured DMNV neurones for 24 h and cultures were fixed
with mixture of acetone and methanol (1 : 1) at −20◦C for
10 min. At room temperature, neurones were incubated
with mouse monoclonal anti-BrdU (5 µg ml−1) for
2 h, followed by FITC-conjugated goat anti-mouse IgG
(Vector Laboratories Inc., Burlingame, CA, USA). BrdU
positive cells were counted in five 20 × microscope fields
per well (at the 12-, 3-, 6-, and 9-o’clock positions and in
the centre). Data were expressed as the percentage of total
cells present.
Results
Expression of ghrelin receptor
Ghrelin receptor, also known as growth hormone
secretagogue receptor, contains seven trans-
membrane (TM) domains and belongs to a family
of G-protein-coupled receptors (Howard et al. 1996;
McKee et al. 1997). Two types of ghrelin receptor cDNA
have been identified: type 1a, encoding a functional
protein containing 7 TM domains, and type 1b,
encoding a protein containing TM-1 through 5 with
no measurable functional activity. Ghrelin receptors are
widely distributed among both central and peripheral
tissues including pituitary gland (Howard et al. 1996),
hypothalamus (Howard et al. 1996), pancreas (Date et al.
2002), stomach and intestine (Date et al. 2000). cDNAs
for human, rat, mouse and swine ghrelin receptor have
been sequenced (Howard et al. 1996; McKee et al. 1997).
To determine if ghrelin receptor is present in DMNV
neurones, RT-PCR analysis was performed using primers
generated from published coding rat ghrelin receptor
sequences. As shown in Fig. 1A, mRNA corresponding
to ghrelin receptor was detected in DMNV tissues
isolated from 3- to 5-day-old rats (n = 5). Sequence
analysis indicates that these mRNAs matched known rat
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nucleotide sequences. As a control for expression level,
the house-keeping gene β-actin mRNA was detected in
all samples. Expression of ghrelin receptor was further
verified by localization of the ghrelin receptor immuno-
reactivity in DMNV neurones using a specific antibody
against the C-terminal sequence 330–366 of the human
ghrelin receptor 1a (Fig. 1B).
Stimulation of neuronal proliferation in vivo
In order to study neurogenesis in the DMNV, we
assayed the BrdU incorporation in adult rats. As
shown in Fig. 2, BrdU labelling (1 ± 0.5, n = 4) was
rare in the DMNV. Systemic administration of ghrelin
(130 nmol kg−1) demonstrated no significant increase
in the BrdU incorporation (3.5 ± 2, n = 4, P > 0.05 as
compared to control). With cervical vagotomy, there was
a significant increase in BrdU labelling in the ipsilateral
DMNV. When ghrelin (130 nmol kg−1) was systemically
administrated in adult rats undergoing vagotomy, BrdU
incorporation was significantly increased relative to rats
with cervical vagotomy that were administrated 0.9% NaCl
(69 ± 14 versus 27 ± 4, P < 0.05).
Stimulation of neuronal proliferation in vitro
To study the mechanism of neurogenesis stimulated by
ghrelin, we established an in vitro model of culture of
Figure 3. Neural precursor cells in cultured DMNV
neurones
DMV neurones cultured for 6–7 days contained neural
precursor cells as demonstrated by expression of the
immature neuronal marker Hu: 78 ± 9% of cells expressed
Hu immunoreactivity; 13 ± 4% of cells stained positive for
MAP-2, identifying them as post-mitotic cells;
GFAP-immunopositive cells, indicative of cells of glial lineage,
were rare (∼1%). Cell nuclei were counterstained with DAPI.
Scale bar represents 100 µm.
DMNV neurones and assayed the effect of ghrelin on
cultured DMNV neural proliferation. DMNV neurones
cultured for 6–7 days contained mature neurones
as demonstrated by expression of neuronal marker,
MAP-2 (13 ± 4%, n = 3), as well as precursor cells as
demonstrated by expression of the immature neuronal
marker, Hu in 78 ± 9% of cells (Fig. 3). Glia fibrillary
acidic protein (GFAP) immunopositive cells in these
cultures were rare (∼1%), indicating that cultures were
free of contaminating astrocytes. When cultured neurones
were induced to differentiate by growing in medium
without βFGF, the number of fully differentiated neurones
increased significantly as demonstrated by the increment
of MAP-2 positive cells (49 ± 8%, n = 4). Exposure of
cultured cells to ghrelin (10−7 m) did not demonstrate any
effect on neuronal differentiation (48 ± 9% of cells stained
positive for MAP-2, n = 4) relative to control.
DMNV neurones were cultured under serum-free
conditions and cell proliferation was assayed. When
cultures were treated with ghrelin for 24 h in vitro,
the number of neurones increased 2.1 ± 0.1-fold, which
was significantly different from control (1.4 ± 0.2, n = 5,
P < 0.05). To further characterize the mitotic effect of
ghrelin, we used BrdU labelling to identify cells undergoing
proliferation. As shown in Fig. 4A, increased incorporation
of BrdU into cells was detected. The ghrelin-mediated
increase in BrdU incorporation was dose dependent within
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the range of 10−9–10−6 m (Fig. 4B), and time dependent
from 6 h to 48 h (Fig. 4C).
In order to identify the nature of proliferating cells,
double immunofluorescent staining was performed. As
shown in Fig. 5, mitotic cells, identified by BrdU labelling,
also stained positive for Hu, a marker for immature and
mature neurones.
Activation of voltage-dependent calcium channels
Postsynaptic L-type voltage-dependent calcium currents
have been reported to activate the MAPK pathway which
then stimulates expression of genes that are essential
for neural survival and plasticity, including nuclear
transcription factor cAMP response element binding
protein (CREB) (Dolmetsch et al. 2001). It is possible
that ghrelin stimulates neurogenesis via the mediation
of L-type calcium channels. To test this possibility, we
Figure 4. Stimulation of BrdU incorporation into cultured
DMNV neurones by ghrelin
A, immunodetection of BrdU labelling in control (upper) and in the
presence of ghrelin (lower). Nuclei were counterstained with DAPI. The
figure shown is representative of three different experiments. Scale bar
represents 100 µm. B, effect of increasing concentrations of ghrelin
on BrdU incorporation in cultured DMNV neurones. C, time-
dependent increases in percentage of BrdU positive cells responding to
ghrelin (10−7 M). Values are means ± S.E.M. ∗P < 0.05.
investigated whether ghrelin affects calcium channels
on DMNV neurones using a whole-cell patch-clamp
technique. Experimental conditions were set to isolate
calcium currents from other voltage-dependent currents.
Calcium current was evoked by stepping the membrane
potential from a holding potential of −90 mV to
potentials between −90 and +60 mV. Calcium current
was first evident with voltage steps to −30 mV, and
reached an average maximal current amplitude of
308 ± 78 pA (n = 13) with membrane depolarization at
10 mV (Fig. 6A). The current was sustained during the
time of recording. As shown in Fig. 6A, application
of ghrelin (10−8 m) significantly increased both the
peak and the plateau phases of the voltage-dependent
calcium currents in 35 ± 9% of DMNV neurones tested
(n = 16). The effect of ghrelin was time dependent with
the peak response at 2.5 min (Fig. 6B). Current–voltage
relationship analysis demonstrated no shift of voltage
activation with ghrelin, suggesting that it does not alter
the voltage sensitivity of activation (Fig. 6C). As shown
in Fig. 6D, ghrelin increased the mean maximal change of
calcium currents from 141 ± 26 pA to 227 ± 37 pA, when
membrane potential was depolarized to 0 mV to induce
submaximal calcium current.
To determine if activation of calcium channels
directly contributes to cell proliferation, cultured DMNV
neurones were treated with diltiazem, a specific L-type
voltage-dependent calcium channel blocker. As shown
in Fig. 6E, treatment of cultured DMNV neurones with
10 µm diltiazem significantly attenuated ghrelin-induced
increases in BrdU incorporation (n = 5, P < 0.05).
Discussion
The major finding of the present study is that ghrelin
stimulates neuronal proliferation in DMNV both in vivo
Figure 5. Stimulation of BrdU incorporation by ghrelin in
neurones
Cultured DMNV cells were treated with ghrelin (10−7 M) for 24 h.
Colocalization of BrdU labelling (Green) with immunoreactivity for the
neuronal marker Hu (Red) was demonstrated by double
immunofluorescent staining. Nuclei were counterstained with DAPI
(Blue). Scale bar represents 50 µm.
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and in vitro. This observation constitutes the first report
of neurogenesis stimulated by ghrelin. This conclusion
is supported by two distinct observations: (1) systemic
administration of ghrelin increases vagotomy-induced
BrdU incorporation in the DMNV in adult rats;
and (2) cultured DMNV neurones respond to ghrelin
with increased BrdU incorporation in both dose- and
time-dependent manners.
Neurogenesis has been demonstrated in the adult
nervous system both under physiological conditions and
subsequent to ischaemic brain injury (Seri et al. 2001;
Alvarez-Buylla & Garcia-Verdugo, 2002; Jin et al. 2002a,b).
Several studies have shown that global or focal cerebral
Figure 6. Calcium currents contribute
to ghrelin-induced increment of BrdU
incorporation in cultured DMNV
neurones
A, representative calcium current
activated by 50 ms voltage step from a
holding potential of −90 mV to 0 mV
prior to, during and following washout of
ghrelin (10−8 M). n = 16. B, representative
time course of change in current
following to application of ghrelin.
C, current–voltage relationship for calcium
current before, during and following
washout of ghrelin (n = 3). D, mean
change of calcium current in the absence
of ghrelin (open bar), in the presence of
ghrelin (filled bar), and following 2 min
washout of ghrelin (stippled bar). n = 6.
∗P < 0.05. E, treatment of cultured
DMNV neurones with 10 µM diltiazem, a
specific L-type voltage-dependent calcium
channel blocker, significantly attenuated
the increment of BrdU incorporation
induced by ghrelin (10−7 M). Values are
means ± S.E.M. n = 5. ∗P < 0.05 versus
ghrelin.
ischaemia stimulates neurogenesis, typically defined by
increased incorporation of BrdU into cells that express
neuronal marker proteins (Jin et al. 2002a,b). Although
the molecular mechanisms remain unknown, neuro-
genesis has been reported to be generated through
the proliferation of radial cells located in the floor
of cerebral ventricles (Seri et al. 2001; Alvarez-Buylla
& Garcia-Verdugo, 2002). The present study examines
neurogenesis in adult brain nuclei surrounding the 4th
cerebral ventricle such as DMNV, the NST and the
area postrema (AP). Although lacking active proliferation
under basal conditions, the dorsal vagal complex (DVC)
responds to perturbation induced by vagotomy with
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an increase in cell proliferation. It has been previously
reported that mechanical or chemical injury such as vagal
axotomy, hypoxia and hypoglycemia results in multiple
neuronal responses in the DVC including activation of
c-fos expression (Yuan & Yang, 2002) and neuronal
degeneration (Chang et al. 2001), suggesting neuronal
plasticity in the DVC.
Neurogenesis in embryos and in adult neural stem cells
is regulated by a group of growth factors including stem
cell factor (Jin et al. 2002a), vascular endothelial growth
factor (VEGF) (Jin et al. 2002b), fibroblast growth factor
(FGF) (Munoz-Sanjuan & Brivanlou, 2002), insulin-like
growth factor (IGF) (Munoz-Sanjuan & Brivanlou, 2002)
and bone morphogenetic protein (BMP) (Munoz-Sanjuan
& Brivanlou, 2002). Based on both in vivo and in vitro
data, ghrelin produced a significant increase in BrdU
incorporation, suggesting its potential to promote neuro-
nal development and regeneration. Both the organization
and phenotype of DMNV neurones projecting to the
gastrointestinal tract undergo extensive specification and
reorganization in the perinatal period (Powley et al. 2001).
The molecular mechanisms that control alteration in vagal
innervation are not clear. In rats, ghrelin-immunoreactive
cells were found to be first expressed at a relatively low level
in the fetal stomach from pregnancy day 18 (Hayashida
et al. 2002). The number of ghrelin-immunoreactive cells
and plasma ghrelin levels increase significantly in the
early postnatal period (Hayashida et al. 2002; Sakata et al.
2002), suggesting that ghrelin may play a role in neonatal
development. It is possible that ghrelin-mediated mitotic
effects on DMNV neurones play a role in the development
of the vagal innervation. Since ghrelin immunoreactivity
is not detected in the DVC (data not shown) and DVC
is devoid of brain–blood barrier, the source of ghrelin
responsible for stimulation of neurogenesis in DMNV may
come from the circulating blood.
The detection of both ghrelin receptor mRNA and
immunoreactivity in DMNV suggests that ghrelin may act
as an extracellular signal molecule to activate its receptor.
The ghrelin receptor has been reported to be expressed in a
variety of tissues ranging from the hypothalamus, pituitary
gland and cerebral cortex in the central nervous system
(Yokote et al. 1998) to the gastrointestinal system (Date
et al. 2000), pancreas (Date et al. 2002), kidney (Mori et al.
2000) and the cardiovascular system (Papotti et al. 2000) in
the peripheral tissues. Activation of the ghrelin receptors
accounts for the diversity of functions that ghrelin exerts
in these tissues.
Activation of ghrelin receptors has been associated
with an increase of intracellular calcium concentration
([Ca2+]i) in several types of cells, including pancreatic
β cells, HEK-293 cells and CHO cells expressing ghrelin
receptor (Kojima et al. 1999; Bednarek et al. 2000; Date
et al. 2002). The increase in [Ca2+]i is mediated by release
of IP3-sensitive stores. Whole-cell patch-clamp recording
suggests that voltage-sensitive calcium channels are
present and may account for the ghrelin-mediated increase
in the [Ca2+]i in DMNV neurones. Previous studies (Chen
et al. 1996) using somatotropes demonstrated that binding
of GHS ligand to the ghrelin receptor leads to an inhibition
of potassium channels, which results in sustained
depolarization of the somatotropes. This depolarization
results in the entry of Ca2+ through voltage-gated
L- and T-type channels. It is still unclear whether ghrelin
activates L-type voltage-dependent calcium channels in
DMNV neurones by inhibition of potassium currents.
The physiological significance of the [Ca2+]i signalling
in DMNV neurones is not clearly understood. However,
[Ca2+]i is an important intracellular second messenger
that regulates many short-term and long-term neuronal
functions ranging from secretion to cell survival. In the
present study, we demonstrated that the mitotic effect
of ghrelin on DMNV neurones is attenuated by blocking
L-type calcium channels by diltiazem.
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